CTL Manufacturing Diagram

A CTL (cytotoxic T-cell) library of inventory is made for each development program.

  1. The process starts with healthy white blood cells (peripheral blood mononuclear cells, or PBMCs) collected from a third-party party donor.
  2. The B-cells are separated and exposed to the target antigen (protein) of interest so they can present the antigen to T-cells.
  3. T-cells from the same third-party party donor, are then exposed to the antigen presenting B-cells. Only those T-cells with a receptor that recognizes the antigen of interest become activated to eliminate target diseased cells, and their numbers significantly expand with activation. Those T-cells unable to recognize the antigen do not become activated and do not expand.
  4. The result is a CTL line enriched with cytotoxic T-cells specifically recognizing the target antigen. This CTL line is characterized by it’s human leukocyte antigen (HLA) and restriction profile and categorized in a library of cryopreserved inventory.
  5. The library is comprised of a relatively small number of ready-to-utilize CTL lines that provide broad coverage to match to each patient’s individual immune profile.